MW 267.33 g/mol. Cell-permeable, potent, selective, reversible, ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 150nM), CDK2/cyclin A (IC50 = 120nM), CDK2/cyclin E (IC50 = 400nM), CDK5/p25 (IC50 = 200nM), CDK5/p35 (IC50 = 160nM) and GSK-3α (IC50 = 500nM). Also inhibits GSK-3β (IC50 = 650nM) and c-Jun N-terminal kinase (JNK) (IC50 = ~3-10μM). Poor inhibitor of CK1, CK2, CDK4/cyclin D1, MAPKK, PKA, PKG, PKCs and c-raf (IC50≥100μM). Blocks cell cycle progression in both G1 and G2 phase.
MW 267.33 g/mol. Cell-permeable, potent, selective, reversible, ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 150nM), CDK2/cyclin A (IC50 = 120nM), CDK2/cyclin E (IC50 = 400nM), CDK5/p25 (IC50 = 200nM), CDK5/p35 (IC50 = 160nM) and GSK-3α (IC50 = 500nM). Also inhibits GSK-3β (IC50 = 650nM) and c-Jun N-terminal kinase (JNK) (IC50 = ~3-10μM). Poor inhibitor of CK1, CK2, CDK4/cyclin D1, MAPKK, PKA, PKG, PKCs and c-raf (IC50≥100μM). Blocks cell cycle progression in both G1 and G2 phase.
DMSO.
Cell-permeable, potent, selective, reversible, ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 150nM), CDK2/cyclin A (IC50 = 120nM), CDK2/cyclin E (IC50 = 400nM), CDK5/p25 (IC50 = 200nM), CDK5/p35 (IC50 = 160nM) and GSK-3α (IC50 = 500nM). Also inhibits GSK-3β (IC50 = 650nM) and c-Jun N-terminal kinase (JNK) (IC50 = ~3-10μM). Poor inhibitor of CK1, CK2, CDK4/cyclin D1, MAPKK, PKA, PKG, PKCs and c-raf (IC50≥100μM). Blocks cell cycle progression in both G1 and G2 phase.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab143750, Aloisine A, CDK inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com